Bispecific Antibodies
•60 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (60)
| Company | Market Cap | Price |
|---|---|---|
|
JNJ
Johnson & Johnson
The company markets bispecific antibodies (TECVAYLI, TALVEY), a distinct antibody modality.
|
$454.86B |
$188.88
-0.09%
|
|
ABBV
AbbVie Inc.
AbbVie is pursuing bispecific antibodies (e.g., ABBV-383), a distinct oncology modality.
|
$385.15B |
$218.07
-4.44%
|
|
AZN
AstraZeneca PLC
IO bispecific antibodies are a key immuno-oncology modality in AZN's pipeline.
|
$255.44B |
$82.39
+0.06%
|
|
MRK
Merck & Co., Inc.
The pipeline includes bispecific antibodies/T-cell engagers developed via acquisitions/collaborations.
|
$215.90B |
$85.99
-0.34%
|
|
AMGN
Amgen Inc.
Amgen leverages a bispecific antibody platform (BiTEs) in its oncology programs (e.g., BLINCYTO) and related assets.
|
$160.47B |
$298.45
+2.21%
|
|
BMY
Bristol-Myers Squibb Company
BioNTech collaboration on BNT327 represents Bispecific Antibodies as a direct modality.
|
$93.77B |
$46.11
+1.07%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
The company is advancing bispecific antibodies (e.g., Lynozyfic, Odronextamab) as a key modality.
|
$69.08B |
$651.52
-0.39%
|
|
BNTX
BioNTech SE
BNT327 is a bispecific antibody (PD-L1 x VEGF-A), a direct Bispecific Antibodies product category.
|
$24.91B |
$103.92
-0.72%
|
|
GMAB
Genmab A/S
Genmab's DuoBody bispecific antibody technology powers its bispecific therapies, aligning with Bispecific Antibodies.
|
$18.93B |
$28.60
-0.24%
|
|
INCY
Incyte Corporation
TGFßR2xPD-1 bispecific represents a distinct antibody modality in development, a separate investable category.
|
$18.25B |
$93.49
+0.97%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$14.05B |
$18.91
+1.45%
|
|
EXEL
Exelixis, Inc.
XB628 is a bispecific antibody developed by Exelixis.
|
$10.55B |
$38.67
-0.69%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$8.48B |
$137.62
+0.97%
|
|
MRUS
Merus N.V.
Technology platforms enable bispecific antibodies (and multispecifics), a primary Merus offering.
|
$6.57B |
$94.86
-0.21%
|
|
CNTA
Centessa Pharmaceuticals plc
LockBody aims to create conditionally-active antibodies engaging CD3, consistent with 'Bispecific Antibodies'.
|
$3.33B |
$24.89
+2.32%
|
|
ZLAB
Zai Lab Limited
Bispecific antibody programs (e.g., dual-target antibodies) advancing in oncology/immunology.
|
$2.83B |
$26.12
+2.37%
|
|
IDYA
IDEAYA Biosciences, Inc.
Pipeline includes a bispecific antibody modality (e.g., IDE034) targeting two cancer-related antigens.
|
$2.79B |
$31.87
+0.85%
|
|
CLDX
Celldex Therapeutics, Inc.
CDX-622 is a bispecific antibody in Celldex's pipeline, aligning with Bispecific Antibodies as a core modality.
|
$1.77B |
$26.70
+2.69%
|
|
JANX
Janux Therapeutics, Inc.
Core product modality is Bispecific Antibodies engineered to engage T cells in a tumor-activated manner.
|
$1.70B |
$28.70
+0.67%
|
|
IMCR
Immunocore Holdings plc
ImmTACs are bispecific TCR constructs; platform enables bispecific modalities.
|
$1.66B |
$33.00
+2.52%
|
|
ABCL
AbCellera Biologics Inc.
T-cell engager / bispecific antibody programs are part of AbCellera's pipeline.
|
$1.66B |
$5.54
+3.36%
|
|
ZYME
Zymeworks Inc.
Zymeworks' portfolio includes bispecific antibodies and multispecific antibody therapeutics (MSATs).
|
$1.33B |
$19.07
-0.26%
|
|
ZBIO
Zenas BioPharma, Inc.
Lead asset obexelimab is a bispecific antibody engaging two targets.
|
$1.31B |
$31.25
+4.60%
|
|
OPK
OPKO Health, Inc.
ModeX Therapeutics' multi-specific antibodies represent a bispecific antibody product category.
|
$1.08B |
$1.34
-7.88%
|
|
IMTX
Immatics N.V.
TCR Bispecifics platform (bispecific antibodies engaging tumor cells and T cells).
|
$1.05B |
$10.19
-2.21%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$1.05B |
$14.70
+4.00%
|
|
KOD
Kodiak Sciences Inc.
KSI-501 and KSI-101 are bispecific proteins, aligning with Bispecific Antibodies.
|
$956.34M |
$18.18
-13.66%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Lead candidate ficerafusp alfa is a bispecific antibody targeting two pathways, fitting Bispecific Antibodies.
|
$886.21M |
$16.24
-1.34%
|
|
VIR
Vir Biotechnology, Inc.
Dual-masked bispecific antibodies (T-cell engagers) constitute a primary oncology platform.
|
$823.90M |
$5.95
+0.34%
|
|
NKTR
Nektar Therapeutics
NKTR-0166 is a bispecific antibody program, fitting Bispecific Antibodies as an investable theme.
|
$805.58M |
$64.90
+3.34%
|
|
MLTX
MoonLake Immunotherapeutics
SLK is a multispecific antibody/ Nanobody targeting IL-17A/F, aligning with the Bispecific Antibodies investable theme.
|
$648.46M |
$10.09
+2.85%
|
|
IMAB
I-Mab
I-Mab's portfolio includes bispecific antibodies (e.g., givastomig and ragistomig), a core modality for multi-target engagement.
|
$533.68M |
$4.64
|
|
CMPX
Compass Therapeutics, Inc.
Core asset strategy centers on Bispecific Antibodies (e.g., DLL4 x VEGF-A; PD-1 x PD-L1; PD-1 x VEGF-A).
|
$517.18M |
$3.73
+0.40%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$511.07M |
$8.66
+14.62%
|
|
CTMX
CytomX Therapeutics, Inc.
The PROBODY platform extends to masked T-cell engagers, aligning with Bispecific Antibodies as a modality.
|
$287.82M |
$3.57
+7.21%
|
|
ACRS
Aclaris Therapeutics, Inc.
ATI-52.00 is a bispecific antibody, fitting the Bispecific Antibodies category.
|
$272.87M |
$2.52
+1.20%
|
|
ZURA
Zura Bio Limited
Tibulizumab is a bispecific antibody targeting IL-17A and BAFF (Bispecific Antibodies).
|
$237.60M |
$3.84
+2.40%
|
|
OABI
OmniAb, Inc.
OmniAb's platforms enable discovery of Bispecific Antibodies (OmniFlic/OmniClic), a major therapeutic modality.
|
$189.62M |
$1.55
+4.03%
|
|
IPHA
Innate Pharma S.A.
ANKET NK cell engagers (e.g., IPH6501) are bispecific antibody-based constructs engaging NK cells with tumor targets.
|
$159.51M |
$1.97
-1.26%
|
|
CGEN
Compugen Ltd.
Rilvegostomig is a PD-1/TIGIT bispecific antibody; CGEN contributes the TIGIT component, aligning with Bispecific Antibodies.
|
$158.48M |
$1.77
+7.58%
|
|
MOLN
Molecular Partners AG
Multi-target engaging modality (Switch-DARPin) aligns with bispecific antibody/category dynamics.
|
$120.62M |
$3.63
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$115.72M |
$17.51
+2.04%
|
|
MGNX
MacroGenics, Inc.
Company develops bispecific antibody therapies via its DART platform, including lorigerlimab.
|
$104.73M |
$1.65
+3.45%
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$97.78M |
$1.08
-3.98%
|
|
STTK
Shattuck Labs, Inc.
Pipeline includes DR3 bispecific antibodies, reflecting a major bsAb product modality.
|
$91.97M |
$1.91
-0.78%
|
|
ADAG
Adagene Inc.
Bispecific antibodies (e.g., ADG138 HER2xCD3 POWERbody) in the pipeline.
|
$78.80M |
$1.78
-7.29%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's CD20 x CD3 bispecific candidate demonstrates a bispecific antibody modality.
|
$76.35M |
$1.27
|
|
HOWL
Werewolf Therapeutics, Inc.
WTX-1011 is a T-cell engager (bispecific) targeting STEAP1, mapping to Bispecific Antibodies.
|
$58.78M |
$1.31
-6.07%
|
|
ANL
Adlai Nortye Ltd. American Depositary Shares
ANL’s AN8025 is a multi-specific antibody fusion protein, aligning with the Bispecific Antibodies category.
|
$52.71M |
$1.42
+2.17%
|
|
LVTX
LAVA Therapeutics N.V.
Gammabody antibodies are bispecific antibodies designed to engage gamma delta T cells for anti-tumor activity.
|
$42.74M |
$1.62
-0.61%
|
|
XLO
Xilio Therapeutics, Inc.
Xilio's masked T cell engager programs (ATACR/SEECR) correspond to Bispecific Antibodies.
|
$41.25M |
$0.80
-0.98%
|
|
BCAB
BioAtla, Inc.
BA3182 is a bispecific EpCAM x CD3 T-cell engager, a bispecific antibody.
|
$40.86M |
$0.70
+0.60%
|
|
AKTX
Akari Therapeutics, Plc
Lead to Bispecific ADC (AKTX-102) using PH1 payload, aligning with Bispecific Antibodies.
|
$37.14M |
$0.76
+4.07%
|
|
IBIO
iBio, Inc.
Pipeline includes Bispecific Antibodies such as TROP-2 x CD3 and MUC16 x CD3, reflecting a Bispecific Antibodies focus.
|
$26.43M |
$1.59
+2.90%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Genmab collaboration targets next-generation bispecific ISACs, indicating a Bispecific Antibodies program.
|
$11.04M |
$5.80
+1.21%
|
|
CBIO
Crescent Biopharma, Inc.
CR-001 is a bispecific antibody (PD-1 x VEGF), fitting the Bispecific Antibodies investable theme.
|
$8.23M |
$12.79
+2.24%
|
|
THAR
Tharimmune, Inc.
THAR's pipeline includes bispecific antibodies (HS1940, HS3215), aligning with Bispecific Antibodies.
|
$7.85M |
$2.94
-1.18%
|
|
INAB
IN8bio, Inc.
The INB-600 gamma-delta T cell engager platform suggests bispecific antibody-like T cell engagers.
|
$5.90M |
$1.93
-3.02%
|
|
HCWB
HCW Biologics Inc.
TRBC-derived immune cell engagers and multi-specific targeting align with Bispecific Antibodies as a modality.
|
$5.57M |
$3.88
-0.77%
|
|
APVO
Aptevo Therapeutics Inc.
APVO's lead therapies are bispecific antibodies (and trispecifics) designed to engage T cells and tumor targets using its ADAPTIR/ADAPTIR-FLEX platforms.
|
$628469 |
$1.54
+10.36%
|
Loading company comparison...
Loading industry trends...
Loading research report...
